schliessen

Filtern

 

Bibliotheken

Vemurafenib in patients with BRAFV600E -positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial

Summary Background About half of patients with papillary thyroid cancer have tumours with activating BRAFV600E mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for BRAF -positive melanoma, showed clinical benefit in three patients with BRAFV600E -positive papillary thyroid cancer... Full description

Journal Title: The lancet oncology 2016, Vol.17 (9), p.1272-1282
Main Author: Brose, Marcia S, Dr
Other Authors: Cabanillas, Maria E, MD , Cohen, Ezra E W, Prof , Wirth, Lori J, MD , Riehl, Todd, PharmD , Yue, Huibin, PhD , Sherman, Steven I, Prof , Sherman, Eric J, MD
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: London: Elsevier Ltd
ID: ISSN: 1470-2045
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5532535
title: Vemurafenib in patients with BRAFV600E -positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
format: Article
creator:
  • Brose, Marcia S, Dr
  • Cabanillas, Maria E, MD
  • Cohen, Ezra E W, Prof
  • Wirth, Lori J, MD
  • Riehl, Todd, PharmD
  • Yue, Huibin, PhD
  • Sherman, Steven I, Prof
  • Sherman, Eric J, MD
subjects:
  • Article
  • Cancer therapies
  • Drug dosages
  • Dyspnea
  • FDA approval
  • Hematology, Oncology and Palliative Medicine
  • Iodine
  • Lymphopenia
  • Medical prognosis
  • Melanoma
  • Metastases
  • Metastasis
  • Mortality
  • Motivation
  • Mutation
  • Papillary thyroid cancer
  • Patients
  • Respiration
  • Skin
  • Squamous cell carcinoma
  • Thyroid
  • Thyroid cancer
  • Tumors
  • Vascular endothelial growth factor receptors
ispartof: The lancet oncology, 2016, Vol.17 (9), p.1272-1282
description: Summary Background About half of patients with papillary thyroid cancer have tumours with activating BRAFV600E mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for BRAF -positive melanoma, showed clinical benefit in three patients with BRAFV600E -positive papillary thyroid cancer in a phase 1 trial. We aimed to establish the activity of vemurafenib in patients with BRAFV600E -positive papillary thyroid cancer. Methods We did an open-label, non-randomised, phase 2 trial at ten academic centres and hospitals worldwide in patients aged 18 years or older with histologically confirmed recurrent or metastatic papillary thyroid cancer refractory to radioactive iodine and positive for the BRAFV600E mutation. Participants either had never received a multikinase inhibitor targeting VEGFR (cohort 1) or had been treated previously with a VEGFR multikinase inhibitor (cohort 2). Patients received vemurafenib 960 mg orally twice daily. The primary endpoint was investigator-assessed best overall response in cohort 1 (confirmed on two assessments 4 weeks or longer apart). Analyses were planned to have a minimum median follow-up of 15 months (data cutoff April 18, 2014) and were done in safety, intention-to-treat, and per-protocol populations. This trial is closed and is registered at ClinicalTrials.gov , number NCT01286753. Findings Between June 23, 2011, and Jan 15, 2013, 51 patients were enrolled to the study, 26 in cohort 1 and 25 in cohort 2. Median duration of follow-up was 18·8 months (IQR 14·2–26·0) in cohort 1 and 12·0 months (6·7–20·3) in cohort 2. Partial responses were recorded in ten of 26 patients in cohort 1 (best overall response 38·5%, 95% CI 20·2–59·4). Grade 3 or 4 adverse events were recorded in 17 (65%) of 26 patients in cohort 1 and 17 (68%) of 25 patients in cohort 2; the most common grade 3 and 4 adverse events were squamous cell carcinoma of the skin (seven [27%] in cohort 1, five [20%] in cohort 2), lymphopenia (two [8%] in each cohort), and increased γ-glutamyltransferase (one [4%] in cohort 1, three [12%] in cohort 2). Two individuals in cohort 2 died due to adverse events, one from dyspnoea and one from multiorgan failure, but neither was treatment related. Serious adverse events were reported for 16 (62%) of 26 patients in cohort 1 and 17 (68%) of 25 patients in cohort 2. Interpretation Vemurafenib showed antitumour activity in patients with progressive, BRAFV600E -positive papillary thyroid cancer refractory to radioactive i
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 1470-2045
fulltext: fulltext
issn:
  • 1470-2045
  • 1474-5488
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.786389
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_pubme
recordidTN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5532535
sourceformatXML
sourcesystemPC
sourcerecordid1827895783
originalsourceidFETCH-LOGICAL-15084-c6f5e82088297d23977a73bccbba85683e23c767d3ed0296e4d3817f06184213
addsrcrecordideNqFkl1rFDEUhgdRbK3-BCHgTYWO5mPysRYqtbRWKAhaehsyyRk3dTYZk5mV_jr_mpndonRvejWT5H2fnHPyVtVrgt8RTMT776SRuKa44YdEvGVlS9TqSbVftpuaN0o93fxvJXvVi5xvMSaSYP682qOyEbhp6H715wZWUzIdBN8iH9BgRg9hzOi3H5fo07fTixuB8Tmqh5j96NeAVjCaPBaZRTGhKSTIYEfT9lDMg-97k-7QuLxL0TtkTbCQUIIuGTvG-SSiZJyPZTnTfHQ-wAdkUIihTia4uPIZ3BFaTX25o9SS4AjFAULdmxb6IzQsTQZE0Zi86V9WzzrTZ3h1_z2ori_Or88u66uvn7-cnV7VhGPV1FZ0HBTFStGFdJQtpDSStda2rVFcKAaUWSmkY-AwXQhoHFNEdlgQ1VDCDqqTLXaY2hW4TVmm10Pyq9KujsbrhyfBL_WPuNacM8oZL4DLLWDuxPgED7wuwKij01RILalsweIFGCIlaYBxa3DXGdkSSlrcFNThfS0p_pogj7pMzEIZfIA4ZU0UlWrBpWJF-mZHehunFMqgioqIhkkmZVHxrcqmmHN5q3-1EaznsOlN2PScJF1Wm7BpVXzHOz7r52DEeQS-f9T9ceuG8mxrD0lnW6JnwZXp2FG76B8lnOwQbO-Dt6b_CXeQ_7eqM9V4C5kZRGwIiv0FVUcDUQ
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1816437377
display
typearticle
titleVemurafenib in patients with BRAFV600E -positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
sourceAlma/SFX Local Collection
creatorBrose, Marcia S, Dr ; Cabanillas, Maria E, MD ; Cohen, Ezra E W, Prof ; Wirth, Lori J, MD ; Riehl, Todd, PharmD ; Yue, Huibin, PhD ; Sherman, Steven I, Prof ; Sherman, Eric J, MD
creatorcontribBrose, Marcia S, Dr ; Cabanillas, Maria E, MD ; Cohen, Ezra E W, Prof ; Wirth, Lori J, MD ; Riehl, Todd, PharmD ; Yue, Huibin, PhD ; Sherman, Steven I, Prof ; Sherman, Eric J, MD
descriptionSummary Background About half of patients with papillary thyroid cancer have tumours with activating BRAFV600E mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for BRAF -positive melanoma, showed clinical benefit in three patients with BRAFV600E -positive papillary thyroid cancer in a phase 1 trial. We aimed to establish the activity of vemurafenib in patients with BRAFV600E -positive papillary thyroid cancer. Methods We did an open-label, non-randomised, phase 2 trial at ten academic centres and hospitals worldwide in patients aged 18 years or older with histologically confirmed recurrent or metastatic papillary thyroid cancer refractory to radioactive iodine and positive for the BRAFV600E mutation. Participants either had never received a multikinase inhibitor targeting VEGFR (cohort 1) or had been treated previously with a VEGFR multikinase inhibitor (cohort 2). Patients received vemurafenib 960 mg orally twice daily. The primary endpoint was investigator-assessed best overall response in cohort 1 (confirmed on two assessments 4 weeks or longer apart). Analyses were planned to have a minimum median follow-up of 15 months (data cutoff April 18, 2014) and were done in safety, intention-to-treat, and per-protocol populations. This trial is closed and is registered at ClinicalTrials.gov , number NCT01286753. Findings Between June 23, 2011, and Jan 15, 2013, 51 patients were enrolled to the study, 26 in cohort 1 and 25 in cohort 2. Median duration of follow-up was 18·8 months (IQR 14·2–26·0) in cohort 1 and 12·0 months (6·7–20·3) in cohort 2. Partial responses were recorded in ten of 26 patients in cohort 1 (best overall response 38·5%, 95% CI 20·2–59·4). Grade 3 or 4 adverse events were recorded in 17 (65%) of 26 patients in cohort 1 and 17 (68%) of 25 patients in cohort 2; the most common grade 3 and 4 adverse events were squamous cell carcinoma of the skin (seven [27%] in cohort 1, five [20%] in cohort 2), lymphopenia (two [8%] in each cohort), and increased γ-glutamyltransferase (one [4%] in cohort 1, three [12%] in cohort 2). Two individuals in cohort 2 died due to adverse events, one from dyspnoea and one from multiorgan failure, but neither was treatment related. Serious adverse events were reported for 16 (62%) of 26 patients in cohort 1 and 17 (68%) of 25 patients in cohort 2. Interpretation Vemurafenib showed antitumour activity in patients with progressive, BRAFV600E -positive papillary thyroid cancer refractory to radioactive iodine who had never been treated with a multikinase inhibitor. As such, this agent represents a potential new treatment option for these patients. Funding F Hoffmann-La Roche.
identifier
0ISSN: 1470-2045
1EISSN: 1474-5488
2DOI: 10.1016/S1470-2045(16)30166-8
3PMID: 27460442
languageeng
publisherLondon: Elsevier Ltd
subjectArticle ; Cancer therapies ; Drug dosages ; Dyspnea ; FDA approval ; Hematology, Oncology and Palliative Medicine ; Iodine ; Lymphopenia ; Medical prognosis ; Melanoma ; Metastases ; Metastasis ; Mortality ; Motivation ; Mutation ; Papillary thyroid cancer ; Patients ; Respiration ; Skin ; Squamous cell carcinoma ; Thyroid ; Thyroid cancer ; Tumors ; Vascular endothelial growth factor receptors
ispartofThe lancet oncology, 2016, Vol.17 (9), p.1272-1282
rights
0Elsevier Ltd
12016 Elsevier Ltd
2Copyright Elsevier Limited Sep 1, 2016
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-15084-c6f5e82088297d23977a73bccbba85683e23c767d3ed0296e4d3817f06184213
citesFETCH-LOGICAL-15084-c6f5e82088297d23977a73bccbba85683e23c767d3ed0296e4d3817f06184213
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
search
creatorcontrib
0Brose, Marcia S, Dr
1Cabanillas, Maria E, MD
2Cohen, Ezra E W, Prof
3Wirth, Lori J, MD
4Riehl, Todd, PharmD
5Yue, Huibin, PhD
6Sherman, Steven I, Prof
7Sherman, Eric J, MD
title
0Vemurafenib in patients with BRAFV600E -positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
1The lancet oncology
descriptionSummary Background About half of patients with papillary thyroid cancer have tumours with activating BRAFV600E mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for BRAF -positive melanoma, showed clinical benefit in three patients with BRAFV600E -positive papillary thyroid cancer in a phase 1 trial. We aimed to establish the activity of vemurafenib in patients with BRAFV600E -positive papillary thyroid cancer. Methods We did an open-label, non-randomised, phase 2 trial at ten academic centres and hospitals worldwide in patients aged 18 years or older with histologically confirmed recurrent or metastatic papillary thyroid cancer refractory to radioactive iodine and positive for the BRAFV600E mutation. Participants either had never received a multikinase inhibitor targeting VEGFR (cohort 1) or had been treated previously with a VEGFR multikinase inhibitor (cohort 2). Patients received vemurafenib 960 mg orally twice daily. The primary endpoint was investigator-assessed best overall response in cohort 1 (confirmed on two assessments 4 weeks or longer apart). Analyses were planned to have a minimum median follow-up of 15 months (data cutoff April 18, 2014) and were done in safety, intention-to-treat, and per-protocol populations. This trial is closed and is registered at ClinicalTrials.gov , number NCT01286753. Findings Between June 23, 2011, and Jan 15, 2013, 51 patients were enrolled to the study, 26 in cohort 1 and 25 in cohort 2. Median duration of follow-up was 18·8 months (IQR 14·2–26·0) in cohort 1 and 12·0 months (6·7–20·3) in cohort 2. Partial responses were recorded in ten of 26 patients in cohort 1 (best overall response 38·5%, 95% CI 20·2–59·4). Grade 3 or 4 adverse events were recorded in 17 (65%) of 26 patients in cohort 1 and 17 (68%) of 25 patients in cohort 2; the most common grade 3 and 4 adverse events were squamous cell carcinoma of the skin (seven [27%] in cohort 1, five [20%] in cohort 2), lymphopenia (two [8%] in each cohort), and increased γ-glutamyltransferase (one [4%] in cohort 1, three [12%] in cohort 2). Two individuals in cohort 2 died due to adverse events, one from dyspnoea and one from multiorgan failure, but neither was treatment related. Serious adverse events were reported for 16 (62%) of 26 patients in cohort 1 and 17 (68%) of 25 patients in cohort 2. Interpretation Vemurafenib showed antitumour activity in patients with progressive, BRAFV600E -positive papillary thyroid cancer refractory to radioactive iodine who had never been treated with a multikinase inhibitor. As such, this agent represents a potential new treatment option for these patients. Funding F Hoffmann-La Roche.
subject
0Article
1Cancer therapies
2Drug dosages
3Dyspnea
4FDA approval
5Hematology, Oncology and Palliative Medicine
6Iodine
7Lymphopenia
8Medical prognosis
9Melanoma
10Metastases
11Metastasis
12Mortality
13Motivation
14Mutation
15Papillary thyroid cancer
16Patients
17Respiration
18Skin
19Squamous cell carcinoma
20Thyroid
21Thyroid cancer
22Tumors
23Vascular endothelial growth factor receptors
issn
01470-2045
11474-5488
fulltexttrue
rsrctypearticle
creationdate2016
recordtypearticle
recordideNqFkl1rFDEUhgdRbK3-BCHgTYWO5mPysRYqtbRWKAhaehsyyRk3dTYZk5mV_jr_mpndonRvejWT5H2fnHPyVtVrgt8RTMT776SRuKa44YdEvGVlS9TqSbVftpuaN0o93fxvJXvVi5xvMSaSYP682qOyEbhp6H715wZWUzIdBN8iH9BgRg9hzOi3H5fo07fTixuB8Tmqh5j96NeAVjCaPBaZRTGhKSTIYEfT9lDMg-97k-7QuLxL0TtkTbCQUIIuGTvG-SSiZJyPZTnTfHQ-wAdkUIihTia4uPIZ3BFaTX25o9SS4AjFAULdmxb6IzQsTQZE0Zi86V9WzzrTZ3h1_z2ori_Or88u66uvn7-cnV7VhGPV1FZ0HBTFStGFdJQtpDSStda2rVFcKAaUWSmkY-AwXQhoHFNEdlgQ1VDCDqqTLXaY2hW4TVmm10Pyq9KujsbrhyfBL_WPuNacM8oZL4DLLWDuxPgED7wuwKij01RILalsweIFGCIlaYBxa3DXGdkSSlrcFNThfS0p_pogj7pMzEIZfIA4ZU0UlWrBpWJF-mZHehunFMqgioqIhkkmZVHxrcqmmHN5q3-1EaznsOlN2PScJF1Wm7BpVXzHOz7r52DEeQS-f9T9ceuG8mxrD0lnW6JnwZXp2FG76B8lnOwQbO-Dt6b_CXeQ_7eqM9V4C5kZRGwIiv0FVUcDUQ
startdate2016
enddate2016
creator
0Brose, Marcia S, Dr
1Cabanillas, Maria E, MD
2Cohen, Ezra E W, Prof
3Wirth, Lori J, MD
4Riehl, Todd, PharmD
5Yue, Huibin, PhD
6Sherman, Steven I, Prof
7Sherman, Eric J, MD
general
0Elsevier Ltd
1Elsevier Limited
scope
0AAYXX
1CITATION
20TZ
33V.
47RV
57TO
67X7
77XB
888E
98AO
108C1
118C2
128FI
138FJ
148FK
15ABUWG
16BENPR
17FYUFA
18GHDGH
19H94
20K9.
21KB0
22M0S
23M1P
24NAPCQ
25PQEST
26PQQKQ
27PQUKI
28PRINS
29BOBZL
30CLFQK
315PM
sort
creationdate2016
titleVemurafenib in patients with BRAFV600E -positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
authorBrose, Marcia S, Dr ; Cabanillas, Maria E, MD ; Cohen, Ezra E W, Prof ; Wirth, Lori J, MD ; Riehl, Todd, PharmD ; Yue, Huibin, PhD ; Sherman, Steven I, Prof ; Sherman, Eric J, MD
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-15084-c6f5e82088297d23977a73bccbba85683e23c767d3ed0296e4d3817f06184213
rsrctypearticles
prefilterarticles
languageeng
creationdate2016
topic
0Article
1Cancer therapies
2Drug dosages
3Dyspnea
4FDA approval
5Hematology, Oncology and Palliative Medicine
6Iodine
7Lymphopenia
8Medical prognosis
9Melanoma
10Metastases
11Metastasis
12Mortality
13Motivation
14Mutation
15Papillary thyroid cancer
16Patients
17Respiration
18Skin
19Squamous cell carcinoma
20Thyroid
21Thyroid cancer
22Tumors
23Vascular endothelial growth factor receptors
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Brose, Marcia S, Dr
1Cabanillas, Maria E, MD
2Cohen, Ezra E W, Prof
3Wirth, Lori J, MD
4Riehl, Todd, PharmD
5Yue, Huibin, PhD
6Sherman, Steven I, Prof
7Sherman, Eric J, MD
collection
0CrossRef
1Pharma and Biotech Premium PRO
2ProQuest Central (Corporate)
3Nursing & Allied Health Database
4Oncogenes and Growth Factors Abstracts
5Health & Medical Collection
6ProQuest Central (purchase pre-March 2016)
7Medical Database (Alumni Edition)
8ProQuest Pharma Collection
9Public Health Database
10Lancet Titles
11Hospital Premium Collection
12Hospital Premium Collection (Alumni Edition)
13ProQuest Central (Alumni) (purchase pre-March 2016)
14ProQuest Central (Alumni Edition)
15ProQuest Central
16Health Research Premium Collection
17Health Research Premium Collection (Alumni)
18AIDS and Cancer Research Abstracts
19ProQuest Health & Medical Complete (Alumni)
20Nursing & Allied Health Database (Alumni Edition)
21Health & Medical Collection (Alumni Edition)
22Medical Database
23Nursing & Allied Health Premium
24ProQuest One Academic Eastern Edition
25ProQuest One Academic
26ProQuest One Academic UKI Edition
27ProQuest Central China
28OpenAIRE (Open Access)
29OpenAIRE
30PubMed Central (Full Participant titles)
jtitleThe lancet oncology
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Brose, Marcia S, Dr
1Cabanillas, Maria E, MD
2Cohen, Ezra E W, Prof
3Wirth, Lori J, MD
4Riehl, Todd, PharmD
5Yue, Huibin, PhD
6Sherman, Steven I, Prof
7Sherman, Eric J, MD
formatjournal
genrearticle
ristypeJOUR
atitleVemurafenib in patients with BRAFV600E -positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
jtitleThe lancet oncology
date2016
risdate2016
volume17
issue9
spage1272
epage1282
pages1272-1282
issn1470-2045
eissn1474-5488
abstractSummary Background About half of patients with papillary thyroid cancer have tumours with activating BRAFV600E mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for BRAF -positive melanoma, showed clinical benefit in three patients with BRAFV600E -positive papillary thyroid cancer in a phase 1 trial. We aimed to establish the activity of vemurafenib in patients with BRAFV600E -positive papillary thyroid cancer. Methods We did an open-label, non-randomised, phase 2 trial at ten academic centres and hospitals worldwide in patients aged 18 years or older with histologically confirmed recurrent or metastatic papillary thyroid cancer refractory to radioactive iodine and positive for the BRAFV600E mutation. Participants either had never received a multikinase inhibitor targeting VEGFR (cohort 1) or had been treated previously with a VEGFR multikinase inhibitor (cohort 2). Patients received vemurafenib 960 mg orally twice daily. The primary endpoint was investigator-assessed best overall response in cohort 1 (confirmed on two assessments 4 weeks or longer apart). Analyses were planned to have a minimum median follow-up of 15 months (data cutoff April 18, 2014) and were done in safety, intention-to-treat, and per-protocol populations. This trial is closed and is registered at ClinicalTrials.gov , number NCT01286753. Findings Between June 23, 2011, and Jan 15, 2013, 51 patients were enrolled to the study, 26 in cohort 1 and 25 in cohort 2. Median duration of follow-up was 18·8 months (IQR 14·2–26·0) in cohort 1 and 12·0 months (6·7–20·3) in cohort 2. Partial responses were recorded in ten of 26 patients in cohort 1 (best overall response 38·5%, 95% CI 20·2–59·4). Grade 3 or 4 adverse events were recorded in 17 (65%) of 26 patients in cohort 1 and 17 (68%) of 25 patients in cohort 2; the most common grade 3 and 4 adverse events were squamous cell carcinoma of the skin (seven [27%] in cohort 1, five [20%] in cohort 2), lymphopenia (two [8%] in each cohort), and increased γ-glutamyltransferase (one [4%] in cohort 1, three [12%] in cohort 2). Two individuals in cohort 2 died due to adverse events, one from dyspnoea and one from multiorgan failure, but neither was treatment related. Serious adverse events were reported for 16 (62%) of 26 patients in cohort 1 and 17 (68%) of 25 patients in cohort 2. Interpretation Vemurafenib showed antitumour activity in patients with progressive, BRAFV600E -positive papillary thyroid cancer refractory to radioactive iodine who had never been treated with a multikinase inhibitor. As such, this agent represents a potential new treatment option for these patients. Funding F Hoffmann-La Roche.
copLondon
pubElsevier Ltd
pmid27460442
doi10.1016/S1470-2045(16)30166-8
oafree_for_read